Home >> Research Area >>Neuroscience>>AChR>> Tiotropium Bromide hydrate

Tiotropium Bromide hydrate

Muscarinic antagonist CAS# 139404-48-1

Tiotropium Bromide hydrate

Catalog No. BCC4585----Order now to get a substantial discount!

Product Name & Size Price Stock
Tiotropium Bromide hydrate: 5mg $92 In Stock
Tiotropium Bromide hydrate: 10mg Please Inquire In Stock
Tiotropium Bromide hydrate: 20mg Please Inquire Please Inquire
Tiotropium Bromide hydrate: 50mg Please Inquire Please Inquire
Tiotropium Bromide hydrate: 100mg Please Inquire Please Inquire
Tiotropium Bromide hydrate: 200mg Please Inquire Please Inquire
Tiotropium Bromide hydrate: 500mg Please Inquire Please Inquire
Tiotropium Bromide hydrate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Tiotropium Bromide hydrate

Number of papers citing our products

Chemical structure

Tiotropium Bromide hydrate

3D structure

Chemical Properties of Tiotropium Bromide hydrate

Cas No. 139404-48-1 SDF Download SDF
PubChem ID 3086654 Appearance Powder
Formula C19H22BrNO4S2 M.Wt 472.4
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO > 10 mM
SMILES C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-]
Standard InChIKey DQHNAVOVODVIMG-CJTHRXGHSA-M
Standard InChI InChI=1S/C19H22NO4S2.BrH/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15;/h3-8,11-13,16-17,22H,9-10H2,1-2H3;1H/q+1;/p-1/t11?,12-,13+,16+,17-;
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Tiotropium Bromide hydrate

DescriptionTiotropium Bromide hydrate is an anticholinergic and bronchodilator and a muscarinic receptor antagonist. Target: mAChR Tiotropium bromide (Ba 679 BR) is a novel potent and long-lasting muscarinic antagonist that has been developed for the treatment of chronic obstructive airways disease (COPD). Binding studies with [3H]tiotropium bromide in human lung have confirmed that this is a potent muscarinic antagonist with equal affinity for M1-, M2- and M3-receptors and is approximately 10-fold more potent than ipratropium bromide. In vitro tiotropium bromide has a potent inhibitory effect against cholinergic nerve-induced contraction of guinea-pig and human airways, that has a slower onset than atropine or ipratropium bromide. tiotropium bromide dissociates slowly from M3-receptors (on airway smooth muscle) but rapidly from M2 autoreceptors (on cholinergic nerve terminals) [1]. Tiotropium bromide is a quaternary ammonium derivative that binds to muscarinic receptors. However, although tiotropium binds with high affinity to muscarinic receptors of M1-, M2- and M3-subtypes, it dissociates very slowly from M1- and M3-receptors but more rapidly from M2-receptors, thereby giving it a unique kinetic selectivity [2].

References:
[1]. Barnes, P.J., et al., Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci, 1995. 56(11-12): p. 853-9. [2]. Hansel, T.T. and P.J. Barnes, Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today (Barc), 2002. 38(9): p. 585-600.

Tiotropium Bromide hydrate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Tiotropium Bromide hydrate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Tiotropium Bromide hydrate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.1169 mL 10.5843 mL 21.1685 mL 42.337 mL 52.9213 mL
5 mM 0.4234 mL 2.1169 mL 4.2337 mL 8.4674 mL 10.5843 mL
10 mM 0.2117 mL 1.0584 mL 2.1169 mL 4.2337 mL 5.2921 mL
50 mM 0.0423 mL 0.2117 mL 0.4234 mL 0.8467 mL 1.0584 mL
100 mM 0.0212 mL 0.1058 mL 0.2117 mL 0.4234 mL 0.5292 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Tiotropium Bromide hydrate

Tiotropium bromide (Ba 679 BR) is a novel potent and long-lasting muscarinic antagonist that has been developed for the treatment of chronic obstructive airways disease (COPD). Binding studies with [3H]tiotropium bromide in human lung have confirmed that

Featured Products
  • Guan-fu base A

    Catalog No.:BCN8491
    CAS No.:1394-48-5
  • TC LPA5 4

    Catalog No.:BCC6267
    CAS No.:1393814-38-4
  • KPT-330

    Catalog No.:BCC4446
    CAS No.:1393477-72-9
  • Thiostrepton

    Catalog No.:BCC7621
    CAS No.:1393-48-2
  • KN-93

    Catalog No.:BCC1683
    CAS No.:139298-40-1
  • MDL 100907

    Catalog No.:BCC7877
    CAS No.:139290-65-6
  • Zolmitriptan

    Catalog No.:BCC5062
    CAS No.:139264-17-8
  • H2L5186303

    Catalog No.:BCC6315
    CAS No.:139262-76-3
  • Fmoc-Lys-OH.HCl

    Catalog No.:BCC3512
    CAS No.:139262-23-0
  • G-36

    Catalog No.:BCC6283
    CAS No.:1392487-51-2
  • Musellarin C

    Catalog No.:BCN7004
    CAS No.:1392476-33-3
  • Musellarin B

    Catalog No.:BCN7192
    CAS No.:1392476-32-2
New Products
 

References on Tiotropium Bromide hydrate

Tiotropium bromide inhibits TGF-beta-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro.[Pubmed:20856827]

Int J Chron Obstruct Pulmon Dis. 2010 Sep 7;5:277-86.

BACKGROUND: chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation and structural alterations (ie, tissue remodeling) throughout the conducting airways, parenchyma, and pulmonary vasculature. Matrix metalloproteinases (MMPs) are extracellular degrading enzymes that play a critical role in inflammatory cell infiltration and tissue remodeling, but the influence of the agents that are used for the treatment of COPD on the production of MMPs is not well understood. PURPOSE: the present study aimed to examine the influence of Tiotropium Bromide hydrate (TBH) on the production of MMPs from lung fibroblasts (LFs) induced by transforming growth factor (TGF)-beta in vitro. METHODS: LFs, at a concentration of 5 x 10(5) cells.mL(-1), were stimulated with TGF-beta in the presence of various concentrations of TBH. MMP-1 and MMP-2 levels in culture supernatants were examined by enzyme-linked immunosorbent assay (ELISA), and MMP messenger ribonucleic acid (mRNA) expression was examined by real-time polymerase chain reaction (RT-PCR). The influence of TBH on TGF-beta signaling pathways was also analyzed by examining Smad activation and signaling protein phosphorylation by ELISA. RESULTS: TBH at more than 15 pg.mL(-1) inhibited the production of MMP-1 and MMP-2, but not tissue inhibitor of matrix metalloproteinase (TIMP)-1 and TIMP-2, from LFs, after TGF-beta stimulation. TBH also suppressed MMP mRNA expression through the inhibition of Smad activation and signaling protein, extracellular-signal-regulated kinase (ERK) 1 and 2, and c-Jun N-terminal kinase (JNK), phosphorylation. CONCLUSION: These results may suggest that TBH suppresses MMP production from LFs, through interference of TGF-beta-mediated signaling pathways and results in favorable modification of the clinical status of COPD.

Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro.[Pubmed:19281093]

Int J Chron Obstruct Pulmon Dis. 2008;3(4):781-9.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by airway remodeling with an accumulation of inflammatory cells. There is also increasing evidence that metalloproteinases (MMPs) may contribute to the pathogenesis of COPD, but the influence of agents that used for the treatment of COPD is not well understood. OBJECTIVE: We evaluated whether Tiotropium Bromide hydrate (TBH), a M3 muscarinic receptor antagonist, could inhibit MMP production from lung fibroblasts (LFs) in response to tumor necrosis factor (TNF)-alpha stimulation. METHODS: LFs were established from normal lung tissues taken from patients with lung tumors. LFs (5 x 10(5) cells/ml) were stimulated with TNF-alpha in the presence of various concentrations of TBH. After 24 h, culture supernatants were obtained and assayed for the levels of MMPs and tissue inhibitor of metalloproteinases (TIMPs) by ELISA. The influence of TBH on mRNA expression of MMPs and TIMPs in 4h-cultured cells was also examined by real-time RT-PCR. Furthermore, nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1) in LFs treated with TBH for 4h was examined by ELISA. RESULTS: TBH at more than 15 pg/ml inhibited the production of MMP-2 from LFs after TNF-alpha stimulation, whereas TIMP-1 and TIMP-2 production was scarcely affected by TBH through the suppression of both mRNA expression and transcription factor, NF-kappaB, activation in LFs induced by TNF-alpha stimulation. CONCLUSION: These results suggest that the attenuating effect of TBH on MMP-2 production from LFs induced by inflammatory stimulation may be additional beneficial therapeutic effects not directly relating to its bronchodilatory effects.

Description

Tiotropium Bromide hydrate is a monohydrate of tiotropium bromide (Spiriva; Tiova; BA 679BR; tiopropium) that is an anticholinergic and bronchodilator and a muscarinic receptor antagonist.

Keywords:

Tiotropium Bromide hydrate,139404-48-1,Natural Products,AChR, buy Tiotropium Bromide hydrate , Tiotropium Bromide hydrate supplier , purchase Tiotropium Bromide hydrate , Tiotropium Bromide hydrate cost , Tiotropium Bromide hydrate manufacturer , order Tiotropium Bromide hydrate , high purity Tiotropium Bromide hydrate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: